Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) have been assigned a consensus recommendation of “Buy” from the nine analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $20.80.

Several equities analysts recently issued reports on the company. BidaskClub upgraded Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. ValuEngine upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 17th. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 10th. Finally, Needham & Company LLC lowered their price target on Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, August 10th.

AMPH traded up $0.02 on Friday, hitting $19.26. 16,234 shares of the stock traded hands, compared to its average volume of 151,461. Amphastar Pharmaceuticals has a 52 week low of $14.40 and a 52 week high of $20.45. The company has a quick ratio of 1.24, a current ratio of 1.94 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $895.06 million, a price-to-earnings ratio of 50.53, a P/E/G ratio of 8.82 and a beta of 1.42.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Wednesday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.05). Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. The firm had revenue of $71.00 million for the quarter, compared to the consensus estimate of $64.22 million. During the same quarter in the prior year, the firm earned $0.11 earnings per share. The company’s revenue was up 8.9% on a year-over-year basis. equities research analysts expect that Amphastar Pharmaceuticals will post 0.1 EPS for the current year.

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 15,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $16.52, for a total transaction of $247,800.00. Following the sale, the director now directly owns 29,845 shares of the company’s stock, valued at $493,039.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jason B. Shandell sold 14,399 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, July 11th. The shares were sold at an average price of $16.77, for a total value of $241,471.23. The disclosure for this sale can be found here. Insiders have sold 45,056 shares of company stock worth $763,305 over the last ninety days. Company insiders own 31.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sei Investments Co. boosted its holdings in shares of Amphastar Pharmaceuticals by 4.9% in the 2nd quarter. Sei Investments Co. now owns 67,934 shares of the company’s stock worth $1,037,000 after acquiring an additional 3,193 shares in the last quarter. Prudential Financial Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 8.4% in the 1st quarter. Prudential Financial Inc. now owns 62,380 shares of the company’s stock worth $1,170,000 after acquiring an additional 4,850 shares in the last quarter. Argent Capital Management LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 2.2% in the 2nd quarter. Argent Capital Management LLC now owns 235,775 shares of the company’s stock worth $3,598,000 after acquiring an additional 5,000 shares in the last quarter. Mackay Shields LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 2.4% in the 2nd quarter. Mackay Shields LLC now owns 234,500 shares of the company’s stock worth $3,578,000 after acquiring an additional 5,500 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 2.2% in the 1st quarter. Principal Financial Group Inc. now owns 273,428 shares of the company’s stock worth $5,127,000 after acquiring an additional 5,789 shares in the last quarter. 43.32% of the stock is currently owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.